Abstract
During the COVID-19 pandemic a number of considerations regarding the interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with rheumatic diseases have arisen.1–4 International initiatives were launched (eg, the COVID-19 Global Rheumatology Alliance and the European League Against Rheumatism COVID-19 Rheumatological Database) aimed at examining the health outcomes of patients with rheumatic diseases and COVID-19 on the basis of sociodemographic factors, comorbidities, clinical presentations of COVID-19, and ongoing immunosuppressive drugs before the virus infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
